Rosanna Smart1, Rosalie Liccardo Pacula1,2,3. 1. Economics, Sociology, and Statistics Department, RAND Corporation, Santa Monica, CA, USA. 2. Health Policy and Management, Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, USA. 3. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.
Abstract
Background: The past decade has seen unprecedented shifts in the cannabis policy environment, and the public health impacts of these changes will hinge on how they affect patterns of cannabis use and the use and harms associated with other substances. Objectives: To review existing research on how state cannabis policy impacts substance use, emphasizing studies using methods for causal inference and highlighting gaps in our understanding of policy impacts on evolving cannabis markets. Methods: Narrative review of quasi-experimental studies for how medical cannabis laws (MCLs) and recreational cannabis laws (RCLs) affect cannabis use and use disorders, as well as the use of or harms from alcohol, opioids, and tobacco. Results: Research suggests MCLs increase adult but not adolescent cannabis use, and provisions of the laws associated with less regulated supply may increase adult cannabis use disorders. These laws may reduce some opioid-related harms, while their impacts on alcohol and tobacco use remain uncertain. Research on RCLs is just emerging, but findings suggest little impact on the prevalence of adolescent cannabis use, potential increases in college student use, and unknown effects on other substance use.Conclusions: Research on how MCLs influence cannabis use has advanced our understanding of the importance of heterogeneity in policies, populations, and market dynamics, but studies of how MCLs relate to other substance use often ignore these factors. Understanding effects of cannabis laws requires greater attention to differences in short- versus long-term effects of the laws, nuances of policies and patterns of consumption, and careful consideration of appropriate control groups.
Background: The past decade has seen unprecedented shifts in the cannabis policy environment, and the public health impacts of these changes will hinge on how they affect patterns of cannabis use and the use and harms associated with other substances. Objectives: To review existing research on how state cannabis policy impacts substance use, emphasizing studies using methods for causal inference and highlighting gaps in our understanding of policy impacts on evolving cannabis markets. Methods: Narrative review of quasi-experimental studies for how medical cannabis laws (MCLs) and recreational cannabis laws (RCLs) affect cannabis use and use disorders, as well as the use of or harms from alcohol, opioids, and tobacco. Results: Research suggests MCLs increase adult but not adolescent cannabis use, and provisions of the laws associated with less regulated supply may increase adult cannabis use disorders. These laws may reduce some opioid-related harms, while their impacts on alcohol and tobacco use remain uncertain. Research on RCLs is just emerging, but findings suggest little impact on the prevalence of adolescent cannabis use, potential increases in college student use, and unknown effects on other substance use.Conclusions: Research on how MCLs influence cannabis use has advanced our understanding of the importance of heterogeneity in policies, populations, and market dynamics, but studies of how MCLs relate to other substance use often ignore these factors. Understanding effects of cannabis laws requires greater attention to differences in short- versus long-term effects of the laws, nuances of policies and patterns of consumption, and careful consideration of appropriate control groups.
Entities:
Keywords:
Cannabis; alcohol; drug policy; opioids; substitution; tobacco
Authors: Matthew N Newmeyer; Madeleine J Swortwood; Osama A Abulseoud; Marilyn A Huestis Journal: Drug Alcohol Depend Date: 2017-03-29 Impact factor: 4.492
Authors: Esther K Choo; Madeline Benz; Nikolas Zaller; Otis Warren; Kristin L Rising; K John McConnell Journal: J Adolesc Health Date: 2014-04-16 Impact factor: 5.012
Authors: Eric R Pedersen; Caislin L Firth; Anthony Rodriguez; Regina A Shih; Rachana Seelam; Lisa Kraus; Michael S Dunbar; Joan S Tucker; Beau Kilmer; Elizabeth J D'Amico Journal: Am J Addict Date: 2020-12-30
Authors: Shannon Gravely; Pete Driezen; Danielle M Smith; Ron Borland; Eric N Lindblom; David Hammond; Ann McNeill; Andrew Hyland; K Michael Cummings; Gary Chan; Mary E Thompson; Christian Boudreau; Nadia Martin; Janine Ouimet; Ruth Loewen; Anne C K Quah; Maciej L Goniewicz; James F Thrasher; Geoffrey T Fong Journal: Int J Drug Policy Date: 2020-04-16
Authors: Alexa J Pellegrino; Kerry D Duck; Dylan P J Kriescher; Mackenzie E Shrake; Michael M Phillips; Trent L Lalonde; Kristina T Phillips Journal: J Drug Issues Date: 2020-07-04
Authors: Johannes Thrul; Jill A Rabinowitz; Beth A Reboussin; Brion S Maher; Nicholas S Ialongo Journal: Addiction Date: 2020-07-21 Impact factor: 6.526
Authors: Jenny L Wiley; Daniel G Barrus; Charlotte E Farquhar; Timothy W Lefever; Thomas F Gamage Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2020-08-15 Impact factor: 5.067
Authors: Jessica L Bourdon; Meredith W Francis; Lena Jia; Chenxue Liang; Helen I Robinson; Richard A Grucza Journal: J Subst Abuse Treat Date: 2021-06-11